CClinicalTrials.gg
CompletedNCT00159029Updated Aug 10, 2017

Genetics of Alpha Thalassemia in Israeli Ethnic Groups

An observational study in Alpha Thalassemia, sponsored by Deborah Rund. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-10.

Sponsored by Deborah Rund · Observational

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Alpha thalassemia causes mild anemia and is found in many ethnic groups. Usually it is found in regions where malaria is endemic. We have found that alpha thalassemia is common in Ashkenazim, whose countries of origin are in temperate climates.

We are analyzing the alpha globin genes of individuals of many ethnic groups and will compare to try to define the origin of thalassemia in these individuals of European extraction.

Read the detailed description

Alpha thalassemia causes mild anemia and is found in many ethnic groups. Usually it is found in regions where malaria is endemic. We have found that alpha thalassemia is common in Ashkenazim, whose countries of origin are in temperate climates.

We are analyzing the alpha globin polymorphisms to determine the haplotypes of individuals of many ethnic groups and will compare to try to define the origin of thalassemia in these individuals of European extraction.

02

Conditions studied

  • Alpha Thalassemia

Browse trials for

03

In context

Thalassemia

416 studies on the registry are indexed under Thalassemia; 67 are open to participants now.

This study's enrollment of 100 is close to the median of 100 across 120 observational studies indexed under Thalassemia.

Browse Thalassemia studies →

Lead sponsor

Deborah Rund is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who come to Hadassah Hospital for anemia with microcytosis who are found to have alpha thalassemia.

Inclusion criteria

  • diagnosis of deletional alpha thalassemia

Exclusion criteria

Exclusion Criteria:

  • under age 18
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
100 participants (actual)
Biospecimen retention
Samples with dna
06

Study locations

1 site
  • Hadassah Medical Organization
    Jerusalem, Israel
07

References and documents

Publications

  • Rund D, Filon D, Jackson N, Asher N, Oron-Karni V, Sacha T, Czekalska S, Oppenheim A. An unexpectedly high frequency of heterozygosity for alpha-thalassemia in Ashkenazi Jews. Blood Cells Mol Dis. 2004 Jul-Aug;33(1):1-3. doi: 10.1016/j.bcmd.2004.04.009. PubMed 15223003 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00159029
Lead sponsor
Deborah Rund
Responsible party
Deborah Rund (Senior Hematologist, Hadassah Medical Organization) — Sponsor-investigator
First posted
Sep 12, 2005
Start date
Apr 1, 2004
Primary completion
Jul 1, 2017
Completion
Jul 1, 2017
Last update
Aug 10, 2017

Study contacts

Deborah Rund, MD
principal investigator · Hadassah Medical Organization

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion